Home › Cancro al seno › Washington
Studi clinici su Cancro al seno nello stato di Washington
52 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Washington.
Città nello stato di Washington
- Seattle39 studi
- Tacoma18 studi
- Spokane8 studi
- Spokane Valley8 studi
- Renton8 studi
- Kirkland7 studi
- Everett5 studi
- Kennewick5 studi
- Bellingham5 studi
- Vancouver4 studi
- Yakima3 studi
- Walla Walla3 studi
Testo ufficiale dello studio (inglese)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Kadlec Clinic Hematology and Onco, Kennewick
- Providence Regional Cancer System, Lacey
- Valley Medical Center Research, Renton
- e altri 1
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Puyallup
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07205822Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- e altri 19
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Northwest Medical Specialties, Puyallup
- Northwest Cancer Specialists, Vancouver
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07102381Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06324357A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Northwest Medical Specialties, PLLC ( Site 0062), Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222267A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
- Cancer Care Northwest ( Site 0003), Spokane
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Northwest Medical Specialties, Bonney Lake
- Northwest Medical Specialties, Federal Way
- Northwest Medical Specialties, Gig Harbor
- e altri 3
In reclutamentoFase 3
Età 60 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Olympia
- Clinical Trial Site, Seattle
- Clinical Trial Site, Vancouver
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwest Medical Specialties, PLLC, Puyallup
- Fred Hutch Cancer Center, Seattle
- MultiCare Cancer Institute, Tacoma
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Swedish Cancer Institute - Edmonds, Edmonds
- Providence Regional Cancer Partnership, Everett
- UW Medicine Valley Medical Center, Renton
- e altri 5
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- University of Washington, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06085833A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Kadlec Clinic Hematology and Oncology, Kennewick
- Swedish Medical Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05894239ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Northwest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Cancer Institute - Issaquah, Issaquah
- Fred Hutch CC at Evergreen HMC, Kirkland
- e altri 9
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 set 2026 · NCT06492616BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06756932A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Cancer Care Northwest, Spokane Valley
In reclutamentoStudio osservazionale
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Swedish Cancer Institute - Edmonds Campus, Edmonds
- Providence Regional Cancer Partnership, Everett
- Swedish Cancer Institute - Issaquah, Seattle
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06790693The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Providence Regional Cancer System-Aberdeen, Aberdeen
- FHCC Overlake, Bellevue
- PeaceHealth Saint Joseph Medical Center, Bellingham
- e altri 24
In reclutamentoFase 3
Età da 18 a 60 · Donne · Aggiornato il 2 set 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Cancer Care Northwest-1 (601 S. Sherman), Spokane
- Cancer Care Northwest_2 (605 E. Holland), Spokane
- Cancer Care Northwest, Spokane Valley
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Fred Hutch Cancer Research, Seattle
In reclutamentoFase 1/2
Età da 18 a 100 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT06726148Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT06518057Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Swedish Cancer Institute, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT07140172Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale
In reclutamentoFase 3
Età da 18 a 50 · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT06748222Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- University Of Washington, Seattle
In reclutamentoFase 1
Età da 18 a 100 · Tutti i sessi · Aggiornato il 29 lug 2026 · NCT06562192A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
In reclutamentoFase 2
Età 8 e oltre · Tutti i sessi · Aggiornato il 27 lug 2026 · NCT05503797A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
- Summit Cancer Centers, Spokane
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT05377996Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT06993844[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 mag 2026 · NCT06502691Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mag 2026 · NCT06757634A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT07062965Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.